Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified DHAP vs Standard DHAP in Relapsed/Refractory DLBCL
NCT07739654Phase 3Recruiting
- Sponsor
- King Edward Medical University
- Start
- Mar 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial of Cisplatin micelle injection (HA132) and cytarabine in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by King Edward Medical University. Primary endpoint: Overall Response Rate at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)cytarabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07739654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739654.